RenovoRx (RNXT) announced that Johns Hopkins Medicine is now initiated to enroll patients with locally advanced pancreatic cancer in the ongoing Phase III TIGeR-PaC clinical trial. The trial is evaluating RenovoRx’s intra-arterial delivery of gemcitabine via the RenovoCath device. Johns Hopkins Medicine’s Valerie Lee was appointed Principal Investigator for the site. RenovoRx expects full enrollment in the trial during 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RNXT:
- RenovoRx Reports Initial Revenue and Clinical Trial Progress
- RenovoRx increases production of RenovoCath
- RenovoRx: Promising Phase 3 Study and Revenue Growth Drive Buy Rating
- RenovoRx Delays Yearly Report Filing
- RenovoRx’s Innovative Approach to Pancreatic Cancer Treatment: A Promising Investment Opportunity